DANYELZA could be an option worth exploring
If your child had an incomplete response* to induction or relapse therapy for high-risk neuroblastoma (HRNB).
*Incomplete response is defined as partial response, minor response, or stable disease to prior therapy.
Typical HRNB treatment journey
Although nobody is fully prepared for the HRNB journey, you might feel more confident about what lies ahead with DANYELZA. Every child’s HRNB experience is different, but common treatment steps might include:
Induction
Chemotherapy
+/- surgery
Goal: Reduce
tumor size
Consolidation
Chemotherapy and
autologous stem cell
transplant (ASCT)
Goal: Remove any
cancer cells left
Maintenance
Treatments reduce
the chance of the disease
coming back
Goal: Prevent cancer
from returning
Relapse
If the disease comes
back after a period of
improvement
Goal: Eliminate or reduce
cancer cells
If your child had an incomplete response (as shown above), HRNB may still be in their bone and/or bone marrow.
The Curie score is a way for doctors to not only measure how much neuroblastoma has spread in the body but also plan future treatment. To get a Curie score, your care team will look at MIBG scans and assess the amount of disease in specific areas of the body.
Other caregivers have been in your shoes. See how they navigated the HRNB journey
One family and an entire community fight back:
When Luke's HRNB relapsed, his local community rallied behind the whole family. See how Luke's courageous parents found their roles in supporting his care.
Why DANYELZA could be right for your child
Get to know DANYELZA
- DANYELZA is specifically approved for difficult-to-treat HRNB
- DANYELZA is the only FDA-approved option for HRNB in the bone and/or bone marrow specifically for relapsed or refractory disease
- It targets a glycolipid called GD2, which is prevalent in neuroblastoma cells, and contributes to their growth and survival
- DANYELZA is not chemotherapy or radiation; it’s immunotherapy. In HRNB, immunotherapy works with the body to target and destroy tumor cells
- It’s supported by 10+ years of clinical trial experience
- It’s available in 70+ administering hospitals
- Approved via FDA’s Accelerated Approval Program, meaning the agency found the early clinical data of DANYELZA to be promising for meeting unmet needs in HRNB
- Only with DANYELZA does your child’s care team have the flexibility to decide where the infusion is given. It can be given in an outpatient setting, and you may be able to go home the same day
A thoughtful, in-depth conversation with Dr. Leonora Slatnick
Caregiver Webinar
- What HRNB means for your child
- What DANYELZA is, and how it works in the body
- What the clinical data show, plus effectiveness and safety
- What families might expect during the treatment journey with DANYELZA
Paid spokesperson – Dr. Slatnick received compensation from Y-mAbs Therapeutics for her participation in this video.